Earnings Movers | JNJ Raises Sales Guidance; AAL, TSM Outlook Fell Short
@Tiger_Earnings：
1. $Johnson & Johnson(JNJ)$ +6.07%: Strong Q2 Results, Raises Full-Year Guidance Amid Medtech Sales Growth Johnson & Johnson, a leading pharmaceutical company, surged by 6% following better-than-expected revenue and adjusted earnings for the second quarter, primarily driven by robust sales growth in its medtech business.EPS: $2.80 adjusted, vs. $2.62 expectedRevenue: $25.53 bln, vs. $24.63 bln expectedFull-year Sales Guidance: $98.80 bln to $99.80 bln, $1 bln higher than April’s forecastsThe company's performance is seen as a key indicator for the broader health sector. The increase in demand for nonurgent surgeries among older adults, following the COVID-19 pandemic, has been a significant factor contributing to the medtech division's